Back to top
more

Natera (NTRA)

(Delayed Data from NSDQ)

$91.66 USD

91.66
567,710

+0.38 (0.42%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $91.70 +0.04 (0.04%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Natera

by Zacks Equity Research

Natera, Inc. (NTRA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 21.05% and 4.96%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Natera (NTRA) This Earnings Season?

by Zacks Equity Research

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 23.33% and 6.88%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 0.00% and 3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Natera (NTRA) is likely to maintain the current high on a number of favorable factors.

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 15.79% and 10.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

46 and You: Genetic Testing = Giant Growth Market

by Kevin Cook

Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.

Natera, Inc.'s Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Natera.

Natera, Inc. (NTRA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Natera, Inc. (NTRA).

OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%

by Zacks Equity Research

OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 8.47% and 0.63%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -4.08% and 6.58%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects

by Zacks Equity Research

PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.

Natera (NTRA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -6.52% and -2.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?

by Zacks Equity Research

Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.

Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?

by Zacks Equity Research

Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.

Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?

by Zacks Equity Research

Obalon (OBLN) is expected to register robust U.S. revenues in Q3, backed by higher reorders from existing accounts and new order bookings.

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -5.77% and 3.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    What's in Store for Penumbra (PEN) This Earnings Season?

    by Zacks Equity Research

    Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.

      Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?

      by Zacks Equity Research

      Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.

        Can The Uptrend Continue for Natera (NTRA)?

        by Zacks Equity Research

        Natera, Inc. (NTRA) has been on the move lately as the stock has climbed in the past four weeks

          Natera (NTRA) Catches Eye: Stock Jumps 6.3%

          by Zacks Equity Research

          Natera (NTRA) shares rose more than 6% in the last trading session, amid huge volumes.

            QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform

            by Zacks Equity Research

            QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.